CLX-110
Late-stage liver disease
DiscoveryActive
Key Facts
About ClexBio
ClexBio is pioneering a novel approach to tissue engineering with its VivoSet™ platform, which creates perfusable, cell-synthesized tissues designed for rapid engraftment and long-term functionality. The company is advancing a preclinical pipeline of therapeutic tissues for liver failure, diabetes, and cardiac repair, aiming to address chronic diseases where traditional drugs and cell therapies fall short. As a private, preclinical company, ClexBio is seeking partnerships to accelerate development and leverage its scalable, automated manufacturing technology. Its core value proposition lies in creating biologically integrated tissues that enable stem cell therapies to achieve durable therapeutic effects.
View full company profile